Sanofi and Inhibrx, Inc. (“Inhibrx”), a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have entered into a definitive agreement under which Sanofi has agreed to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx. INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue.
Read the full article: Sanofi to Acquire Inhibrx, Inc. //
Source: https://www.globenewswire.com/news-release/2024/01/23/2813696/0/en/Press-Release-Sanofi-to-acquire-Inhibrx-Inc-adding-potential-best-in-class-rare-disease-asset-for-Alpha-1-Antitrypsin-Deficiency-to-pipeline.html